SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is facing sharp after-hours volatility as investors react to a post-earnings sell-off, driven by softer-than-expected guidance for the upcoming quarter and the announcement that co-founder Reed Hastings will step down from the board. While the community remains deeply divided, active discussions focus on debating whether this dip serves as a prime buying opportunity for long-term holders or a confirmation of a shifting narrative following the company's recent failed acquisition attempts.

XRP is a decentralized digital asset and the native token of the XRP Ledger, a Layer 1 blockchain designed for high-performance global payments. Its primary value proposition is offering a fast, cost-effective alternative to traditional banking systems by enabling near-instant cross-border settlements that finalize in three to five seconds. By serving as a neutral bridge asset between different fiat currencies, it helps financial institutions lower liquidity costs and eliminates the need for pre-funded accounts.  The network is unique because it utilizes a federated consensus protocol instead of energy-intensive mining or staking. This system achieves deterministic finality through a Unique Node List of trusted validators who must reach an eighty percent agreement threshold to permanently record transactions. This infrastructure supports a sustained throughput of 1,500 transactions per second and includes a built-in decentralized exchange that allows for the automated trading of any tokenized asset without intermediaries.  The project traces its origins back to 2004 with Ryan Fugger before being co-founded in its modern form by Jed McCaleb and Chris Larsen. The company, now known as Ripple, works with major financial institutions as partners and investors to build global payment solutions. To protect the network from spam, a small amount of XRP is burned during every transaction, and the token is further utilized by institutions as collateral to access traditional markets and manage digital asset infrastructure.  Institutional adoption of the asset reached a major milestone in November 2025 when the SEC approved the first wave of spot XRP ETFs. These products, offered by major issuers including Bitwise, Grayscale, 21Shares, Canary Capital, and Franklin Templeton, are now listed on prominent exchanges like the NYSE Arca, Nasdaq, and Cboe BZX. While Ripple remains a key contributor to the ecosystem, the underlying XRP Ledger continues to operate as an open-source and decentralized network.

Ripple

The XRP community is intensely focused on the potential passage of the Clarity Act, which many traders view as the primary catalyst for long-term institutional adoption and price appreciation. While sentiment remains polarized between optimistic holders awaiting regulatory milestones and critics pointing to lagging performance and supply concerns, active discussions are dominated by debates over its utility versus other major cryptocurrencies and intense speculation regarding its future role in global payment infrastructure.

Newcourt Acquisition Corp. is a blank check company, which engages in the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The company was founded on February 25, 2021 and is headquartered in Oakland, CA.

Psyence Biomedical Ltd.

Psyence Biomedical is experiencing extreme volatility and intense community discussion following a report that a potential executive order regarding ibogaine research could be signed soon. While retail traders are actively debating the stock's parabolic movement and potential for a short squeeze due to its low float, skeptics are highlighting long-term concerns regarding reverse splits and persistent dilution.

Operates as a holding company with interest in providing social shopping platform solutions

WeShop Holdings Ltd - Ordinary Shares - Class A

WeShop Holdings Limited

WeShop Holdings is seeing intense retail-trader speculation and volatility, characterized by rapid price swings, multiple trading halts, and heavy community debate over whether it functions as a short-squeeze opportunity or a high-risk pump and dump. Traders are closely monitoring the stock's low-float setup, with many comparing the recent momentum to other recent high-volatility runners in the microcap sector.

Verizon Communications, Inc. is a holding company, which engages in the provision of communications, information, and entertainment products and services. It operates through the Consumer and Business segments. The Consumer segment provides consumer-focused wireless and wire line communications services and products. The Business segment offers wireless and wireline communications services and products, including FWA broadband, data, video and conferencing services, corporate networking solutions, security and managed network services, local and long-distance voice services, and network access to deliver various IoT services and products. The company was founded in 1983 and is headquartered in New York, NY.

Verizon Communications Inc

Verizon Communications Inc.

Verizon is trending as investors weigh strong earnings and a massive multi-year share buyback program against ongoing concerns over debt levels and competitive pressures. The community is actively debating the stock's role as a defensive income play while monitoring recent management shakeups and the company's aggressive fiber expansion.

The Last Play is Crypto’s 401k.  RETIRE is more than a coin; it’s The Last Play. We are a community dedicated to breaking free from the grind and building true generational wealth. With RETIRE, our mission is simple yet profound: to provide a pathway to retire yourself and secure financial freedom for your bloodline. While others chase hype and trends, we’re focused on creating a legacy that lasts beyond the typical cycle. RETIRE is about making the one move that matters, with a vision for long-term value, freedom, and impact. This isn’t just a meme —it’s a purpose-driven commitment to building a legacy.

The Last Play

$RETIRE is trending as the community rallies around the narrative of replacing traditional, outdated retirement plans with a tokenized, decentralized movement. Supporters are actively discussing a consistent DCA strategy and viewing recent market volatility as a prime opportunity to accumulate, driven by a shared goal of achieving long-term financial freedom.

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

IREN Limited

IREN is seeing significant institutional accumulation and positive momentum as the community monitors the upcoming Sweetwater 1 energization and potential partnership catalysts. While the stock navigates a high-volatility phase, investors are actively debating the company's long-term valuation as an AI-compute platform compared to its infrastructure-focused peers.

Back in 2011, long before “crypto Twitter”, NFTs, or VC-backed chains existed, users of the BitcoinTalk forum came up with a new currency - not to launch a network, but to make fun of btc.... and so: The first memecoin/memecurrency was born.  On May 23, 2011, a Something Awful poster cracked, “Has anyone called them buttcoins yet?”. It was sophomoric and perfect. Within weeks the gag metastasized into Buttcoin.org, a parody blog that described a “peer to peer butt” economy while cataloging mining fiascos, exchange blowups, and MLM-adjacent “innovations”.

Buttcoin

Buttcoin is gaining attention as the internet's original parody token from 2011, with the community highlighting its authentic roots and cultural longevity as key differentiators. Proponents are actively debating its transition from a satirical forum joke to an on-chain asset, emphasizing its survival across market cycles as a signal of long-term potential.

Rumble, Inc. engages in operating an online neutral video platform. It operates through the following geographical segments: United States, Canada, and Other. The company was founded in October 2013 by Chris Pavlovski and is headquartered in Longboat Key, FL.

Rumble Inc - Ordinary Shares - Class A

Rumble Inc

Rumble Inc. is trending as investors rally around the pending acquisition of Northern Data AG, fueling intense speculation about a potential short squeeze due to high short interest and limited share availability. The community is heavily focused on the company's expanding AI and cloud infrastructure capabilities, bolstered by significant capital commitments and partnerships from Tether, which many see as a catalyst for a major valuation re-rate.

Sidus Space, Inc. is a space-as-a-service company. The firm focuses on commercial satellite design, manufacture, launch planning, mission operations and in-orbit support, and data collection with a vision to demonstrate space operations for new technologies, and deliver data and predictive analytics to both domestic and global customers. The company was founded by Carol M. Craig on July 17, 2012 and is headquartered in Merritt Island, FL.

Sidus Space Inc - Ordinary Shares - Class A

Sidus Space is generating significant community interest, driven by its involvement in the Artemis program and ongoing strategic partnerships within the space and defense sectors. Investors are closely monitoring the stock's technical performance and breakout potential, while actively debating the impact of upcoming industry events and broader sector momentum.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Eli Lilly issued a revenue guidance between $80 billion and $83 billion for fiscal 2026</li><li>For the full year 2025, Eli Lilly’s revenue grew 45% to $65.18 billion.</li><li>CFO Lucas Montarce said the company expects to launch the multidose Zepbound within the next 30 days, according to a Bloomberg report.</li></ul>Shares of Eli Lilly (LLY) jumped 8% in pre-market trading on Wednesday, after the company reported better-than-expected fourth-quarter results and issued a revenue guidance between $80 billion and $83 billion for fiscal 2026, significantly above fiscal 2025 revenue.<a href="https://stocktwits.com/symbol/LLY">LLY shares</a> were up 9.2% after the opening bell.Fourth-quarter revenue surged 43% to $19.3 billion, driven by volume growth from Mounjaro and Zepbound – signalling sustained momentum in its obesity and diabetes portfolio. Analysts had expected a revenue of $17.86 billion, according to Fiscal.ai data. Meanwhile, Q4 earnings increased by 51% to $7.39 per share on a reported basis, compared to Street estimates of $7.22 per share.For the full year, Eli Lilly’s revenue grew 45% to $65.18 billion. LLY expects earnings of $33.50 to $35 per share for full-year 2026.<h2 class="st-heading-2">Mounjaro And Zepbound Drive Revenue Growth</h2>Global revenue for Mounjaro surged 110% to $7.4 billion in Q4 2025, with U.S. sales rising 57% to $4.1 billion on strong demand despite lower realized prices. International revenue jumped to $3.3 billion from $899 million a year earlier, driven mainly by volume growth.U.S. Zepbound revenue climbed 122% to $4.2 billion, fueled by higher demand but partially offset by pricing pressure. Meanwhile, revenue from Verzenio, Eli Lilly’s drug to treat metastatic breast cancer, edged up 3% to $1.6 billion.<h2 class="st-heading-2">Eli Lilly’s Product Pipeline</h2>After the FDA authorized Lilly to market Zepbound in a multidose device last month, CFO Lucas Montarce said the company expects to launch the multidose pen within the next 30 days, according to a report by Bloomberg on Wednesday.In an interview with CNBC last month, CEO Dave Ricks said the upcoming Medicare coverage for obesity drugs could significantly boost the launch of its experimental weight-loss pill, Orforglipron. Ricks added that the company expects Medicare coverage to begin immediately after the drug’s launch.<h2 class="st-heading-2">LLY Pulls Ahead As NOVO Faces Headwinds</h2>Eli Lilly’s optimistic outlook stands in stark contrast to Novo Nordisk (NVO), which expects adjusted sales to decline between 5% and 13% and operating profit to drop by up to 13%. The company cited pricing pressure, intensifying competition, and upcoming patent expiries for the key ingredients in Wegovy and Ozempic in select markets outside the U.S.“This is just more evidence they are dominating the category,” Mizuho’s Jared Holz told Bloomberg of Eli Lilly’s obesity market position. “Novo is playing from behind and everyone knows it.”<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment on Stocktwits turned ‘bullish’ from ‘bearish’ over the past 24 hours, amid ‘high’ message volumes.<figure class="image"><img src="https://news.stocktwits-cdn.com/LLY_jpg_1dcca688cf.webp" alt="LLY.jpg" width="933" height="102"><figcaption>LLY's Sentiment Meter and Message Volumes on Feb. 4, 2026 | Source: Stocktwits</figcaption></figure>One user said that Lilly proved that with “a good product comes great demand.”<stembedurl>https://stocktwits.com/Bagholding_VKTX/message/643931351</stembedurl>LLY shares have gained around 25% over the past year.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/novo-nordisk-fda-higher-dose-wegovy-nvo-stock-outlook/cZbjThlR4ZM">Novo Awaits FDA Call On Higher-Dose Wegovy In Early 2026 – NVO Stock Extends Decline Pre-Market On Weak Guidance</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, an Eli Lilly and Company logo seen displayed on a smartphone. (Photo Illustration by Igor Golovniov/SOPA Images/LightRocket via Getty Images)

LLY Stock Surges On Q4  Beat – Obesity, Diabetes Drugs Drive Strong FY26 Outlook

LLY Stock - Fourth-quarter revenue surged 43% to $19.3 billion, above Street estimates of $17.86 billion, according to Fiscal.ai data.

Equity

Fourth-quarter revenue surged 43% to $19.3 billion, above Street estimates of $17.86 billion, according to Fiscal.ai data.

<ul class="summary-bullets"><li>The decision follows a comprehensive review that found no link between GLP-1 RA use and suicidal ideation or behavior.</li><li>The agency conducted a large meta-analysis of 91 placebo-controlled clinical trials involving 107,910 patients.</li><li>The FDA also reviewed data from more than 2.2 million patients using healthcare claims and found no higher risk of self-harm among GLP-1 users versus patients taking other diabetes drugs.</li></ul>The U.S. Food and Drug Administration (FDA) on Tuesday asked drugmakers to remove warnings about suicidal thoughts and behavior from the labels of certain popular weight-loss medications after finding no evidence of increased risk.The request applies to glucagon-like peptide-1 receptor agonists (GLP-1 RAs) approved for obesity, including Novo Nordisk’s (NVO) Wegovy and Saxenda, and Eli Lilly’s (LLY) Zepbound.The decision follows a comprehensive review that found no link between GLP-1 RA use and suicidal ideation or behavior.These warnings were originally included as a precaution, based largely on reports tied to older weight-loss drugs rather than GLP-1 therapies specifically. Notably, GLP-1 medications approved for type 2 diabetes have never carried such warnings, and the FDA said the change will ensure consistent labeling across the drug class.<h2 class="st-heading-2">FDA’s Analysis</h2>The agency conducted a large meta-analysis of 91 placebo-controlled clinical trials involving 107,910 patients. The analysis found no increased risk of suicidal thoughts, self-injurious behavior (SI/B), or other psychiatric adverse events such as depression or anxiety.The FDA also reviewed data from more than 2.2 million patients using healthcare claims and found no higher risk of intentional self-harm among GLP-1 users compared with patients taking other diabetes drugs.The findings reaffirm results from a preliminary FDA review released in early 2024 and align with conclusions from a separate UK review in the same year. The Medicines and Healthcare products Regulatory Agency (MHRA) had found no evidence linking weight-loss and diabetes drugs to suicides or suicidal thoughts.At the time of writing, <a href="https://stocktwits.com/symbol/LLY">LLY</a> and <a href="https://stocktwits.com/symbol/NVO">NVO</a> stocks were trading 0.1% and 0.2% lower, respectively. Retail sentiment for both stocks was in the ‘bullish’ territory.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-did-bctx-stock-surge-50-today/cmUX95vR4Ic">Why Did BCTX Stock Surge 90% Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

 In this photo illustration, the United States Food and Drug Administration (FDA) logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

FDA Clears Popular Weight-Loss Drugs Of Suicide Risk After Review Of Over 100K Patients, Asks Drugmakers To Remove Warnings

The request applies to GLP-1 RAs approved for obesity, including Novo Nordisk’s Wegovy and Saxenda and Eli Lilly’s Zepbound.

LLYX
Defiance Daily Target 2X Long LLY ETF

Feed

News

Sentiment

Fundamentals

Info

Latest LLYX News

LLYXDefiance Daily Target 2X Long LLY ETF